Trident Lifeline Share Price

Trident Lifeline Limited was originally incorporated as Private Limited Company as Trident Lifeline Private Limited on January 09, 2014. Subsequently, Company converted into a Public Limited and the name of Company was changed to Trident Lifeline Limited on June 10, 2022. The Company established itself as a growing force in the pharmaceutical industry, distinguished by a focus on innovation and disciplined expansion. It operates a hybrid business model that combines its own and contract manufacturing with direct exports, allowing it to scale efficiently and serve diverse geographies including India, Africa, Latin America, the CIS region and Asia. Its product portfolio spans key therapeutic areas including antibacterial, antidiabetic, antihypertensive, antilipidemic, proton pump inhibitor and nutraceutical categories, alongside cosmetic and herbal products through its subsidiaries.The Company deal in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. The product portfolio comprises of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Nonsteriodal antiinflammatory drug (NSAIDS). Company made an Initial Public Offering (IPO) of 34,99,200 Equity Shares of face value Rs 10/ each by raising funds from public aggregating to Rs 35.3 Crore in September, 2022. The Company acquired 51% equity stake in TNS Pharma Private Limited, making it a subsidiary of the Company in 2023, TLL Herbal Limited became a subsidiary Company pursuant to acquisition of 51% equity shares w.e.f. August 10, 2023.The Company incorporated TLL Elements Private Limited as wholly owned subsidiary of the Company on April 15, 2024. Further, on 2ndDecember 2024, the Company acquired a 51% equity stake in TLL Parenterals Limited, which specializes in manufacturing a wide range of pharmaceutical products and medicinal products.Subsequently, on 4th February 2025, Company acquired a 51% equity stake in Trident Mediquip Limited.